Semen enhances HIV infectivity and impairs the antiviral efficacy of microbicides

Science Translational Medicine

Volumn 6, Issue 262, 2014, Pages

  Zirafi, Onofrio ^a   Kim, Kyeong Ae ^a   Roan, Nadia R ^b,c   Kluge, Silvia F ^a   Müller, Janis A ^a   Jiang, Shibo ^d   Mayer, Benjamin ^e   Greene, Warner C ^b   Kirchhoff, Frank ^a   Münch, Jan ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NEW YORK BLOOD CENTER   (United States)

^e UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2G12 NEUTRALIZING ANTIBODY; AMYLOID; ANTIVIRUS AGENT; ASTODRIMER; CELLULOSE SULFATE; ELVITEGRAVIR; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INDINAVIR; MARAVIROC; MICROBICIDE; NEUTRALIZING ANTIBODY; NEUTRALIZING ANTIBODY 2F5; POLYANION; POLYMER; POLYNAPHTHALENE SULFONATE; POLYSTYRENE ACID; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIINFECTIVE AGENT; DENDRIMER; POLYLYSINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; HOST CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; NONHUMAN; SEXUAL TRANSMISSION; SPERM; TARGET CELL; TOPICAL TREATMENT; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS TRANSMISSION; CELL LINE; CELL SURVIVAL; CHEMISTRY; FEMALE; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IC50; PATHOGENICITY; TUMOR CELL LINE; VIROLOGY;

ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; DENDRIMERS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; POLYLYSINE; SEMEN;

EID: 84910633007     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3009634     Document Type: Article

References (52)

1. W. C. Koff, D. R. Burton, P. R. Johnson, B. D. Walker, C. R. King, G. J. Nabel, R. Ahmed, M. K. Bhan, S. A. Plotkin, Accelerating next-generation vaccine development for global disease prevention. Science 340, 1232910 (2013).
2. R. M. Grant, D. Hamer, T. Hope, R. Johnston, J. Lange, M. M. Lederman, J. Lieberman, C. J. Miller, J. P. Moore, D. E. Mosier, D. D. Richman, R. T. Schooley, M. S. Springer, R. S. Veazey, M. A. Wainberg, Whither or wither microbicides? Science 321, 532-534 (2008).
3. C. Vanpouille, A. Arakelyan, L. Margolis, Microbicides: Still a long road to success. Trends Microbiol. 20, 369-375 (2012).
4. R. N. Fichorova, L. D. Tucker, D. J. Anderson, The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J. Infect. Dis. 184, 418-428 (2001).
5. S. McCormack, G. Ramjee, A. Kamali, H. Rees, A. M. Crook, M. Gafos, U. Jentsch, R. Pool, M. Chisembele, S. Kapiga, R. Mutemwa, A. Vallely, T. Palanee, Y. Sookrajh, C. J. Lacey, J. Darbyshire, H. Grosskurth, A. Profy, A. Nunn, R. Hayes, J. Weber, PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): A phase 3, randomised, doubleblind, parallel-group trial. Lancet 376, 1329-1337 (2010).
6. Q. Abdool Karim, S. S. Abdool Karim, J. A. Frohlich, A. C. Grobler, C. Baxter, L. E. Mansoor, A. B. Kharsany, S. Sibeko, K. P. Mlisana, Z. Omar, T. N. Gengiah, S. Maarschalk, N. Arulappan, M. Mlotshwa, L. Morris, D. Taylor; CAPRISA 004 Trial Group, Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329, 1168-1174 (2010).
7. J. Marrazzo, G. Ramjee, G. Nair, T. Palanee, B. Mkhize, C. Nakabiito, M. Taljaard, J. Piper, K. Gomez, M. Chirenje; for the VOICE Team, Pre-exposure prophylaxis for HIV in women: Daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003), paper presented at the 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, 3 to 6 March 2013.
8. J. Münch, E. Rücker, L. Ständker, K. Adermann, C. Goffinet, M. Schindler, S. Wildum, R. Chinnadurai, D. Rajan, A. Specht, G. Giménez-Gallego, P. C. Sánchez, D. M. Fowler, A. Koulov, J. W. Kelly, W. Mothes, J. C. Grivel, L. Margolis, O. T. Keppler, W. G. Forssmann, F. Kirchhoff, Semen-derived amyloid fibrils drastically enhance HIV infection. Cell 131, 1059-1071 (2007)
9. I. Hauber, H. Hohenberg, B. Holstermann, W. Hunstein, J. Hauber, The main green tea polyphenol epigallocatechin-3-gallate counteracts semen-mediated enhancement of HIV infection. Proc. Natl. Acad. Sci. U.S.A. 106, 9033-9038 (2009).
10. N. R. Roan, S. Sowinski, J. Münch, F. Kirchhoff, W. C. Greene, Aminoquinoline surfen inhibits the action of SEVI (semen-derived enhancer of viral infection). J. Biol. Chem. 285, 1861-1869 (2010).
11. J. S. Olsen, C. Brown, C. C. Capule, M. Rubinshtein, T. M. Doran, R. K. Srivastava, C. Feng, B. L. Nilsson, J. Yang, S. Dewhurst, Amyloid-binding small molecules efficiently block SEVI (semen-derived enhancer of virus infection)- and semen-mediated enhancement of HIV-1 infection. J. Biol. Chem. 285, 35488-35496 (2010).
12. N. R. Roan, J. A. Müller, H. Liu, S. Chu, F. Arnold, C. M. Stürzel, P. Walther, M. Dong, H. E. Witkowska, F. Kirchhoff, J. Münch, W. C. Greene, Peptides released by physiological cleavage of semen coagulum proteins form amyloids that enhance HIV infection. Cell Host Microbe 10, 541-550 (2011).
13. K. A. Kim, M. Yolamanova, O. Zirafi, N. R. Roan, L. Staendker, W. G. Forssmann, A. Burgener, N. Dejucq-Rainsford, B. H. Hahn, G. M. Shaw, W. C. Greene, F. Kirchhoff, J. Münch, Semen-mediated enhancement of HIV infection is donor-dependent and correlates with the levels of SEVI. Retrovirology 7, 55 (2010).
14. D. I. Bernstein, L. R. Stanberry, S. Sacks, N. K. Ayisi, Y. H. Gong, J. Ireland, R. J. Mumper, G. Holan, B. Matthews, T. McCarthy, N. Bourne, Evaluations of unformulated and formulated dendrimer-based microbicide candidates in mouse and guinea pig models of genital herpes. Antimicrob. Agents Chemother. 47, 3784-3788 (2003).
15. C. F. Price, D. Tyssen, S. Sonza, A. Davie, S. Evans, G. R. Lewis, S. Xia, T. Spelman, P. Hodsman, T. R. Moench, A. Humberstone, J. R. Paull, G. Tachedjian, SPL7013 gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans. PLOS One 6, e24095 (2011).
16. I. McGowan, K. Gomez, K. Bruder, I. Febo, B. A. Chen, B. A. Richardson, M. Husnik, E. Livant, C. Price, C. Jacobson; the MTN-004 Protocol Team, Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004). AIDS 25, 1057-1064 (2011).
17. C. Ochsenbauer, T. G. Edmonds, H. Ding, B. F. Keele, J. Decker, M. G. Salazar, J. F. Salazar-Gonzalez, R. Shattock, B. F. Haynes, G. M. Shaw, B. H. Hahn, J. C. Kappes, Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J. Virol. 86, 2715-2728 (2012).
18. P. Mohan, D. Schols, M. Baba, E. De Clercq, Sulfonic acid polymers as a new class of human immunodeficiency virus inhibitors. Antiviral Res. 18, 139-150 (1992).
19. S. Rusconi, M. Moonis, D. P. Merrill, P. V. Pallai, E. A. Neidhardt, S. K. Singh, K. J. Willis, M. S. Osburne, A. T. Profy, J. C. Jenson, M. S. Hirsch, Naphthalene sulfonate polymers with CD4-blocking and antihuman immunodeficiency virus type 1 activities. Antimicrob. Agents Chemother. 40, 234-236 (1996).
20. D. Huskens, K. Vermeire, A. T. Profy, D. Schols, The candidate sulfonated microbicide, PRO 2000, has potential multiple mechanisms of action against HIV-1. Antiviral Res. 84, 38-47 (2009).
21. I. A. Scordi-Bello, A. Mosoian, C. He, Y. Chen, Y. Cheng, G. A. Jarvis, M. J. Keller, K. Hogarty, D. P. Waller, A. T. Profy, B. C. Herold, M. E. Klotman, Candidate sulfonated and sulfated topical microbicides: Comparison of anti-human immunodeficiency virus activities and mechanisms of action. Antimicrob. Agents Chemother. 49, 3607-3615 (2005).
22. L. Van Damme, R. Govinden, F. M. Mirembe, F. Guédou, S. Solomon, M. L. Becker, B. S. Pradeep, A. K. Krishnan, M. Alary, B. Pande, G. Ramjee, J. Deese, T. Crucitti, D. Taylor; CS Study Group, Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N. Engl. J. Med. 359, 463-472 (2008).
23. S. S. Adool Karim, B. A. Richardson, G. Ramjee, I. F. Hoffman, Z. M. Chirenje, T. Taha, M. Kapina, L. Maslankowski, A. Coletti, A. Profy, T. R. Moench, E. Piwowar-Manning, B. Mâsse, S. L. Hillier, L. Soto-Torres; HIV Prevention Trials Network (HPTN) 035 Study Team, Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS 25, 957-966 (2011).
24. N. R. Roan, H. Liu, S. M. Usmani, J. Neidleman, J. A. Müller, A. Avila-Herrera, A. Gawanbacht, O. Zirafi, S. Chu, M. Dong, S. T. Kumar, J. F. Smith, K. S. Pollard, M. Fändrich, F. Kirchhoff, J. Münch, H. E. Witkowska, W. C. Greene, Liquefaction of semen generates and later degrades a conserved semenogelin peptide that enhances HIV infection. J. Virol. 88, 7221-7234 (2014).
25. G. Fätkenheuer, A. L. Pozniak, M. A. Johnson, A. Plettenberg, S. Staszewski, A. I. Hoepelman, M. S. Saag, F. D. Goebel, J. K. Rockstroh, B. J. Dezube, T. M. Jenkins, C. Medhurst, J. F. Sullivan, C. Ridgway, S. Abel, I. T. James, M. Youle, E. van der Ryst, Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med. 11, 1170-1172 (2005).
26. R. S. Veazey, T. J. Ketas, J. Dufour, T. Moroney-Rasmussen, L. C. Green, P. J. Klasse, J. P. Moore, Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J. Infect. Dis. 202, 739-744 (2010).
27. J. B. Dumond, K. B. Patterson, A. L. Pecha, R. E. Werner, E. Andrews, B. Damle, R. Tressler, J. Worsley, A. D. Kashuba, Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J. Acquir. Immune Defic. Syndr. 51, 546-553 (2009).
28. Q. A. Karim, C. Baxter, Microbicides for the prevention of sexually transmitted HIV infection. Expert Rev. Anti. Infect. Ther. 11, 13-23 (2013).
29. A. R. Neurath, N. Strick, Y. Y. Li, Role of seminal plasma in the anti-HIV-1 activity of candidate microbicides. BMC Infect. Dis. 6, 150 (2006).
30. C. Lackman-Smith, C. Osterling, K. Luckenbaugh, M. Mankowski, B. Snyder, G. Lewis, J. Paull, A. Profy, R. G. Ptak, R. W. Buckheit Jr., K. M. Watson, J. E. Cummins Jr., B. E. Sanders-Beer, Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides. Antimicrob. Agents Chemother. 52, 1768-1781 (2008).
31. S. Tan, L. Lu, L. Li, J. Liu, Y. Oksov, H. Lu, S. Jiang, S. Liu, Polyanionic candidate microbicides accelerate the formation of semen-derived amyloid fibrils to enhance HIV-1 infection. PLOS One 8, e59777 (2013).
32. M. J. Keller, P. M. Mesquita, N. M. Torres, S. Cho, G. Shust, R. P. Madan, H. W. Cohen, J. Petrie, T. Ford, L. Soto-Torres, A. T. Profy, B. C. Herold, Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: Implications for future microbicide clinical trials. PLOS One 5, e87812010 (2010).
33. B. C. Herold, P. M. Mesquita, R. P. Madan, M. J. Keller, Female genital tract secretions and semen impact the development of microbicides for the prevention of HIV and other sexually transmitted infections. Am. J. Reprod. Immunol. 65, 325-333 (2011).
34. S. Patel, E. Hazrati, N. Cheshenko, B. Galen, H. Yang, E. Guzman, R. Wang, B. C. Herold, M. J. Keller, Seminal plasma reduces the effectiveness of topical polyanionic microbicides. J. Infect. Dis. 196, 1394-1402 (2007).
35. F. Arnold, J. Schnell, O. Zirafi, C. Stürzel, C. Meier, T. Weil, L. Ständker, W. G. Forssmann, N. R. Roan, W. C. Greene, F. Kirchhoff, J. Münch, Naturally occurring fragments from two distinct regions of the prostatic acid phosphatase form amyloidogenic enhancers of HIV infection. J. Virol. 86, 1244-1249 (2012).
36. S. M. Usmani, O. Zirafi, J. A. Müller, N. L. Sandi-Monroy, J. K. Yadav, C. Meier, T. Weil, N. R. Roan, W. C. Greene, P. Walther, K. P. Nilsson, P. Hammarström, R. Wetzel, C. D. Pilcher, F. Gagsteiger, M. Fändrich, F. Kirchhoff, J. Münch, Direct visualization of HIV-enhancing endogenous amyloid fibrils in human semen. Nat. Commun. 5, 3508 (2014).
37. I. Mondor, S. Ugolini, Q. J. Sattentau, Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans. J. Virol. 72, 3623-3634 (1998).
38. M. Yolamanova, C. Meier, A. K. Shaytan, V. Vas, C. W. Bertoncini, F. Arnold, O. Zirafi, S. M. Usmani, J. A. Müller, D. Sauter, C. Goffinet, D. Palesch, P. Walther, N. R. Roan, H. Geiger, O. Lunov, T. Simmet, J. Bohne, H. Schrezenmeier, K. Schwarz, L. Ständker, W. G. Forssmann, X. Salvatella, P. G. Khalatur, A. R. Khokhlov, T. P. Knowles, T. Weil, F. Kirchhoff, J. Münch, Peptide nanofibrils boost retroviral gene transfer and provide a rapid means for concentrating viruses. Nat. Nanotechnol. 8, 130-136 (2013).
39. A. Sigal, J. T. Kim, A. B. Balazs, E. Dekel, A. Mayo, R. Milo, D. Baltimore, Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 477, 95-98 (2011).
40. J. Garcia-Perez, P. Rueda, J. Alcami, D. Rognan, F. Arenzana-Seisdedos, B. Lagane, E. Kellenberger, Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5). J. Biol. Chem. 286, 33409-33421 (2011).
41. Q. Tan, Y. Zhu, J. Li, Z. Chen, G. W. Han, I. Kufareva, T. Li, L. Ma, G. Fenalti, J. Li, W. Zhang, X. Xie, H. Yang, H. Jiang, V. Cherezov, H. Liu, R. C. Stevens, Q. Zhao, B. Wu, Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 341, 1387-1390 (2013).
42. K. B. Collins, B. K. Patterson, G. J. Naus, D. V. Landers, P. Gupta, Development of an in vitro organ culture model to study transmission of HIV-1 in the female genital tract. Nat. Med. 6, 475-479 (2000).
43. A. M. Fox-Canale, T. J. Hope, J. Martinson, J. R. Lurain, A. W. Rademaker, J. W. Bremer, A. Landay, G. T. Spear, N. S. Lurain, Human cytomegalovirus and human immunodeficiency virus type-1 co-infection in human cervical tissue. Virology 369, 55-68 (2007).
44. P. Greenhead, P. Hayes, P. S. Watts, K. G. Laing, G. E. Griffin, R. J. Shattock, Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J. Virol. 74, 5577-5586 (2000).
45. P. Fletcher, Y. Kiselyeva, G. Wallace, J. Romano, G. Griffin, L. Margolis, R. Shattock, The non-nucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells. J. Virol. 79, 11179-11186 (2005).
46. J. E. Cummins Jr., J. Guarner, L. Flowers, P. C. Guenthner, J. Bartlett, T. Morken, L. A. Grohskopf, L. Paxton, C. S. Dezzutti, Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture. Antimicrob. Agents Chemother. 51, 1770-1779 (2007).
47. J. Münch, U. Sauermann, M. Yolamanova, K. Raue, C. Stahl-Hennig, F. Kirchhoff, Effect of semen and seminal amyloid on vaginal transmission of simian immunodeficiency virus. Retrovirology 10, 148 (2013).
48. G. Q. Del Prete, B. Ailers, B. Moldt, B. F. Keele, J. D. Estes, A. Rodriguez, M. Sampias, K. Oswald, R. Fast, C. M. Trubey, E. Chertova, J. Smedley, C. C. LaBranche, D. C. Montefiori, D. R. Burton, G. M. Shaw, M. Markowitz, M. Piatak Jr., V. N. KewalRamani, P. D. Bieniasz, J. D. Lifson, T. Hatziioannou, Selection of unadapted, pathogenic SHIVs encoding newly transmitted HIV-1 envelope proteins. Cell Host Microbe 16, 412-418 (2014).
49. C. C. Capule, C. Brown, J. S. Olsen, S. Dewhurst, J. Yang, Oligovalent amyloid-binding agents reduce SEVI-mediated enhancement of HIV-1 infection. J. Am. Chem. Soc. 134, 905-908 (2012).
50. J. Yang, L. Li, H. Jin, S. Tan, J. Qiu, L. Yang, Y. Ding, Z. H. Jiang, S. Jiang, S. Liu, Vaginal gel formulation based on theaflavin derivatives as a microbicide to prevent HIV sexual transmission. AIDS Res. Hum. Retroviruses 28, 1498-1508 (2012).
51. S. R. Sheftic, J. M. Snell, S. Jha, A. T. Alexandrescu, Inhibition of semen-derived enhancer of virus infection (SEVI) fibrillogenesis by zinc and copper. Eur. Biophys. J. 41, 695-704 (2012).
52. S. A. Sievers, J. Karanicolas, H. W. Chang, A. Zhao, L. Jiang, O. Zirafi, J. T. Stevens, J. Münch, D. Baker, D. Eisenberg, Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation. Nature 475, 96-100 (2011).